Continental Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Continental Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.86M	Sell	232,118 -10,000	-4%	-$333K	3.32%	5
2026 Q1	$7.29M	Sell	242,118 -46,000	-16%	-$1.48M	3.72%	5
2025 Q4	$8.99M	Sell	288,118 -53,000	-16%	-$1.31M	3.8%	5
2025 Q3	$6.89M	Hold	341,118	–	–	2.98%	12
2025 Q2	$5.72M	Hold	341,118	–	–	2.68%	13
2025 Q1	$5.24M	Hold	341,118	–	–	2.93%	13
2024 Q4	$7.52M	Sell	341,118 -20,500	-6%	-$373K	3.46%	7
2024 Q3	$6.52M	Sell	361,618 -42,148	-10%	-$738K	3.14%	10
2024 Q2	$6.56M	Sell	403,766 -74,000	-15%	-$1.14M	2.88%	9
2024 Q1	$6.74M	Buy	477,766 +162,900	+52%	+$2.05M	2.72%	10
2023 Q4	$3.29M	Sell	314,866 -26,000	-8%	-$243K	1.28%	24
2023 Q3	$3.48M	Sell	340,866 -72,500	-18%	-$675K	1.85%	20
2023 Q2	$3.11M	Buy	413,366 +43,566	+12%	+$353K	1.41%	23
2023 Q1	$3.27M	Buy	369,800 +63,500	+21%	+$628K	1.75%	20
2022 Q4	$2.79M	Buy	306,300 +131,000	+75%	+$1.14M	1.46%	26
2022 Q3	$1.42M	Sell	175,300 -78,186	-31%	-$691K	0.83%	42
2022 Q2	$1.91M	Sell	253,486 -25,000	-9%	-$218K	1.15%	34
2022 Q1	$2.62M	Sell	278,486 -10,000	-3%	-$83.5K	1.29%	29
2021 Q4	$2.31M	Hold	288,486	–	–	0.97%	35
2021 Q3	$2.81M	Buy	288,486 +29,000	+11%	+$272K	1.19%	33
2021 Q2	$2.57M	Buy	259,486 +10,000	+4%	+$106K	1.18%	29
2021 Q1	$2.88M	Sell	249,486 -10,000	-4%	-$115K	1.33%	30
2020 Q4	$2.5M	Buy	259,486 +126,300	+95%	+$1.21M	1.14%	35
2020 Q3	$1.2M	Sell	133,186 -30,000	-18%	-$317K	0.64%	55
2020 Q2	$2.01M	Hold	163,186	–	–	1.08%	40
2020 Q1	$1.47M	Hold	163,186	–	–	1.09%	43
2019 Q4	$1.6M	Sell	163,186 -8,057	-5%	-$71.9K	0.77%	47
2019 Q3	$1.18M	Hold	171,243	–	–	0.7%	54
2019 Q2	$1.58M	Hold	171,243	–	–	0.89%	46
2019 Q1	$2.69M	Sell	171,243 -59,057	-26%	-$1.04M	1.25%	28
2018 Q4	$3.55M	Hold	230,300	–	–	1.08%	35
2018 Q3	$4.96M	Sell	230,300 -36,800	-14%	-$854K	1.08%	32
2018 Q2	$6.5M	Sell	267,100 -76,680	-22%	-$1.56M	1.62%	20
2018 Q1	$5.88M	Buy	343,780 +51,000	+17%	+$996K	1.49%	24
2017 Q4	$5.55M	Buy	292,780 +37,880	+15%	+$570K	1.2%	26
2017 Q3	$4.49M	Buy	254,900 +143,500	+129%	+$3.23M	1.03%	33
2017 Q2	$3.7M	Buy	111,400 +43,300	+64%	+$1.34M	0.84%	44
2017 Q1	$2.19M	Buy	68,100 +25,500	+60%	+$870K	0.49%	59
2016 Q4	$1.54M	Buy	42,600 +10,600	+33%	+$423K	0.42%	77
2016 Q3	$1.47M	Hold	32,000	–	–	0.41%	75
2016 Q2	$1.61M	Hold	32,000	–	–	0.5%	67
2016 Q1	$1.71M	Hold	32,000	–	–	0.48%	61
2015 Q4	$2.1M	Hold	32,000	–	–	0.53%	60
2015 Q3	$1.81M	Sell	32,000 -11,500	-26%	-$746K	0.49%	66
2015 Q2	$2.57M	Sell	43,500 -11,000	-20%	-$679K	0.68%	54
2015 Q1	$3.4M	Sell	54,500 -12,000	-18%	-$698K	0.75%	47
2014 Q4	$3.82M	Hold	66,500	–	–	0.77%	38
2014 Q3	$3.57M	Sell	66,500 -18,500	-22%	-$980K	0.81%	33
2014 Q2	$4.46M	Sell	85,000 -4,000	-4%	-$204K	1.04%	26
2014 Q1	$4.7M	Sell	89,000 -32,197	-27%	-$1.49M	1.21%	21
2013 Q4	$4.86M	Buy	121,197 +30,000	+33%	+$1.18M	1.06%	23
2013 Q3	$3.44M	Buy	91,197 +24,897	+38%	+$971K	0.86%	30
2013 Q2	$2.6M	Buy	+66,300	New	+$2.58M	0.73%	43

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Continental Advisors's TEVA Position: Q2 2026 in Review

Continental Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 4.1% in Q2 2026, selling an estimated $333K and leaving 232,118 shares worth $7.86M. The position accounts for 3.32% of the portfolio, ranked #5.

Continental Advisors first reported a position in TEVA in Q2 2013 and has held it in 53 quarters since. The position peaked at $8.99M in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Continental Advisors held 232,118 shares of Teva Pharmaceuticals worth $7.86M as of Q2 2026.
Continental Advisors sold 10,000 Teva Pharmaceuticals shares in Q2 2026, an estimated $333K.
Teva Pharmaceuticals made up 3.32% of Continental Advisors's portfolio in Q2 2026, its #5 holding.
Continental Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
Continental Advisors's Teva Pharmaceuticals position peaked at $8.99M in Q4 2025.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Continental Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.